SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: zurdo who wrote (4727)8/4/1998 5:04:00 PM
From: Dave  Read Replies (1) | Respond to of 9523
 
In a correcting market like the one we have now...the overvalued blue chips are going to get hit extra hard. They've been on a long run and are due for a correction. If you look at the smaller cap stocks, those companies that have low PEs and are undervalued relative to the blue chips that have been on a tear for a number of years, you will see they were hit less hard today. All of this is very general of course and all IMHO.

PFE is a great stock and will continue to be an excellent long term play.



To: zurdo who wrote (4727)8/4/1998 5:24:00 PM
From: Anthony Wong  Read Replies (2) | Respond to of 9523
 
zurdo, the high P/E big pharmas have corrected more than the others (such as MRK) in today's big sell-off:

WLA - 8.37%
BMY - 4.67%
PFE - 4.5%
SGP - 3.98%
JNJ - 2.81%
MRK - 1.9%

To illustrate Dave's point, CA and PG (not lesser stocks, but they've corrected) are both up today.

No bad news on any of the big pharmas. The most recent Celebra news is the article at Post#4725.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News